Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Revenue (2020 - 2025)

Historic Revenue for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to $90000.0.

  • 4D Molecular Therapeutics' Revenue rose 290000.0% to $90000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $120000.0, marking a year-over-year increase of 60588.24%. This contributed to the annual value of $37000.0 for FY2024, which is 9982.15% down from last year.
  • 4D Molecular Therapeutics' Revenue amounted to $90000.0 in Q3 2025, which was up 290000.0% from $15000.0 recorded in Q2 2025.
  • 4D Molecular Therapeutics' Revenue's 5-year high stood at $20.2 million during Q3 2023, with a 5-year trough of -$19000.0 in Q4 2023.
  • In the last 5 years, 4D Molecular Therapeutics' Revenue had a median value of $162000.0 in 2022 and averaged $2.2 million.
  • The largest annual percentage gain for 4D Molecular Therapeutics' Revenue in the last 5 years was 394080.0% (2023), contrasted with its biggest fall of 10152.37% (2023).
  • 4D Molecular Therapeutics' Revenue (Quarter) stood at $92000.0 in 2021, then skyrocketed by 1255.43% to $1.2 million in 2022, then tumbled by 101.52% to -$19000.0 in 2023, then soared by 105.26% to $1000.0 in 2024, then soared by 8900.0% to $90000.0 in 2025.
  • Its Revenue stands at $90000.0 for Q3 2025, versus $15000.0 for Q2 2025 and $14000.0 for Q1 2025.